NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.ambrivis.comABVC BioPharma has been granted an additional 180-day period by Nasdaq to regain compliance with its $1.0 per share minimum bid price requirement, with the new deadline set for July 7, 2025. This extension allows the biopharmaceutical company, which focuses on treatments in ophthalmology, CNS, and oncology/hematology, more time to meet Nasdaq's listing standards. ABVC must achieve a closing bid price of at least $1 per share for a minimum of 10 consecutive business days to satisfy the compliance requirement. The company intends to monitor its stock price closely and implement strategic measures to ensure compliance and enhance shareholder value. ABVC remains compliant with other Nasdaq requirements, including the market value of publicly held shares and shareholder equity thresholds.
Compliance DeadlineABVC Biopharma, Inc. faces a deadline on October 21, 2025, to submit a compliance plan to Nasdaq after being notified of non-compliance with listing standards due to insufficient stockholders’ equity reported at $723,959 as of April 23, 2025. The company needs to demonstrate a viable plan that indicates the potential to regain compliance within 180 days to avoid possible delisting. The lingering risk of delisting could adversely affect liquidity, pricing of its common stock, and overall investor confidence.
Deadline for Compliance Plan Submission